CombinAble.AI

Tailored Antibody Optimization

Health Tech & Life Sciences
Acquired by insitro on Jan 2026
Follow

Company Overview

Snapshot

Founded in August 2023 by Daria Kokh, CombinAble.AI operates with 1–10 employees. The company was acquired by insitro in January 2026, following a funding round in March 2024.

Business overview

CombinAble.AI is a Health Tech & Life Sciences company that revolutionizes therapeutic design through its AI platform. The company's core technology enables the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers. By accelerating the development timeline for biologics, CombinAble.AI provides a competitive advantage to its partners in the biopharmaceutical, biotechnology, and pharmaceutical industries.

Strategic signal

In January 2026, CombinAble.AI was acquired by insitro, a move that significantly enhances insitro's capabilities by integrating CombinAble.AI's AI platform for targeted antibody design. This acquisition signals a strong market validation for AI-driven drug discovery platforms and underscores the growing trend of leveraging artificial intelligence to accelerate and optimize the development of complex therapeutics, offering a strategic advantage in the drug development landscape.

Log in to access full profile

Company Intelligence Q&A

What was a significant recent corporate development for CombinAble.AI?
CombinAble.AI was acquired by insitro in January 2026. This acquisition aimed to complete insitro's full-stack, modality-agnostic AI platform for drug discovery and design.
When was CombinAble.AI founded and by whom?
CombinAble.AI was founded in August 2023 by Co-founder & CEO Daria Kokh.
What is CombinAble.AI's primary focus in therapeutic design?
CombinAble.AI focuses on the rapid in silico development of complex antibody formats, including bi-specifics, tri-specifics, and T-cell engagers, using its unique AI platform.
What is the reported benefit of CombinAble.AI's platform for drug development?
The platform enables the development of best-in-class therapeutics in approximately four months, significantly faster than traditional methods, providing a competitive advantage for complex biologics.
Log in to access full profile